Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Isolated limb perfusion for extremity sarcoma.

B W Feig1

  • 1Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 106, Houston, TX 77030. bwfeig@mdanderson.org

Current Oncology Reports
|December 21, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Raining Frogs, Flying Horses, and Defining Tumor Rupture in GIST.

Annals of surgical oncology·2019
Same author

Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard.

Scientific reports·2017
Same author

Impact of multimodal therapy in locally recurrent rectal cancer.

The British journal of surgery·2016
Same author

Metaplastic sarcomatoid carcinoma of the breast appears more aggressive than other triple receptor-negative breast cancers.

Breast cancer research and treatment·2011
Same author

A pilot study evaluating predictors of postoperative outcomes after major abdominal surgery: Physiological capacity compared with the ASA physical status classification system.

British journal of anaesthesia·2010
Same author

Postoperative nomogram for survival of patients with retroperitoneal sarcoma treated with curative intent.

Annals of oncology : official journal of the European Society for Medical Oncology·2009
Same journal

Revisiting the Immunological Landscape of Locoregional Therapies for Gastrointestinal Cancers: A Shift Toward Interventional Immuno-Oncology.

Current oncology reports·2026
Same journal

Anti-PD-1 Combinations: Triplets and Beyond.

Current oncology reports·2026
Same journal

Sacituzumab Tirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases.

Current oncology reports·2026
Same journal

Clusterin in Head and Neck Squamous Cell Carcinoma: Diagnostic, Prognostic, and Therapeutic Implications.

Current oncology reports·2026
Same journal

Cardiac Risk Without a Roadmap: Lack of Evidence-Based Guidance for Cardiovascular Toxicity of T-Cell Redirecting Therapies.

Current oncology reports·2026
Same journal

Current Understanding of CHIP's Immunobiological Footprint with A Focus on Gastrointestinal Disorders: A Review of the Literature.

Current oncology reports·2026
See all related articles

Isolated limb perfusion offers a limb-sparing option for extremity sarcomas. However, optimal drug choices, hyperthermia

Area of Science:

  • Oncology
  • Surgical Oncology
  • Pharmacology

Background:

  • Isolated limb perfusion (ILP) has been a limb-sparing treatment for extremity sarcomas for over four decades.
  • It is typically considered when amputation is the only alternative treatment.
  • Despite its long history, significant questions persist regarding its optimal application.

Purpose of the Study:

  • To review the current understanding and unresolved questions in isolated limb perfusion for extremity sarcomas.
  • To critically evaluate the role of specific chemotherapeutic agents and hyperthermia in ILP.
  • To identify limitations in existing research and suggest future directions.

Main Methods:

  • Review of non-randomized studies on isolated limb perfusion for extremity sarcomas.

Related Experiment Videos

  • Analysis of data concerning chemotherapeutic agents, hyperthermia protocols, and treatment settings (neoadjuvant/adjuvant).
  • Evaluation of study limitations including small patient numbers and subjective outcome assessments.

    • Main Results:

    • Non-randomized studies show variability in chemotherapeutic agents and hyperthermia levels used.
    • Subjective evaluation of amputation as a treatment option complicates outcome assessment.
    • Lack of standardized protocols hinders definitive conclusions on ILP efficacy.

    Conclusions:

    • Further research, including randomized controlled trials, is needed to optimize ILP protocols for extremity sarcomas.
    • Standardization of chemotherapeutic agents, hyperthermia, and outcome measures is crucial.
    • Clarifying the role of ILP in neoadjuvant and adjuvant settings requires more robust evidence.